© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Scientists love to chase after ideas that can really shake up how we battle disease. Roflumilast’s start comes from a long search for therapies that dial down inflammation without knocking the immune system out entirely. Back in the late 1990s, breathing problems like chronic obstructive pulmonary disease (COPD) were tearing through communities, leaving folks short of breath and often out of options. Researchers went digging deep into a class of molecules called phosphodiesterase-4 inhibitors, searching for a way to slow the inflammation that clogs airways. Roflumilast jumped out because it went after the PDE4 enzyme with serious selectivity, trimming the inflammatory signal without the broad, sometimes brutal, effects of corticosteroids. After years of lab work and clinical trials, it became the first oral PDE4 inhibitor approved for daily use against COPD. When the green light finally came, it didn’t just add another pill to the shelf—it signaled a new way to think about taming runaway inflammation.
You don’t need to wear a lab coat to sense that a molecule’s shape and structure decide how it behaves. Roflumilast’s core contains a fused aromatic ring system with a signature cyano group and a methoxycarbonyl substituent. These aren’t just chemical curiosities—they steer the molecule toward PDE4 and give it the punch it needs to stop inflammation at its roots. Roflumilast typically appears as a white to off-white powder, not flashy but reliable, with limited water solubility. That’s a big reason for its specific dosing strategies: a steady oral dose gets better results than tossing in large, erratic amounts. Melting at around 104-106°C, it stays stable under reasonable storage, so clinicians and patients alike can trust the product even outside fancy hospital storage.
A closer look at Roflumilast’s technical specs shows why manufacturers fret over every step. Pure Roflumilast has the formula C17H14Cl2N2O3, and weighs in with a molecular mass of about 403 grams per mole. Small details carry weight. A stray impurity or a tweak in the synthetic route can shift patient outcomes. It breaks down slowly, which means lower risk of sudden activity surges in the body. Labels spell out its purpose, target patient groups—mainly adults with severe COPD—and warn against use in people with already depleted immune systems or active liver disease. It pays to read the label; that’s where you learn to look for side effects like weight loss or mood changes, which, though rare, need quick attention.
Anyone who’s set foot in a chemistry lab knows making a drug like Roflumilast takes patience and grit. You start with aromatic nitriles and stack on groups piece by piece, leading the molecules down a reaction pathway like a well-marked hiking trail. Each setup demands specific temperature controls and solvents—no room for shortcuts or guesswork. Isolation, filtration, and purification draw out the good stuff, followed by crystallization or drying to lock in consistency. Along the way, plant chemists keep close checks on every batch to pin down unwanted by-products. Changes to its chemical structure have paved the way for studies into topical creams for scalp psoriasis and even other airway diseases, showing just how tweakable this core scaffold can be. Sometimes the small shifts—a missing methyl group, a swap from chloride to fluoride—turn the basic molecule into a fresh candidate for research.
Drug names often confuse more than they enlighten. Roflumilast can pop up under brand names like Daxas or Daliresp, but in labs and pharmacy records, you’ll also run across handles like 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-difluoromethoxybenzamide. Each version signals a different use, market, or research focus. For clinicians, knowing the synonyms helps guard against mix-ups and keeps treatment on target. Even in the world of generic competition, sticking to a consistent nomenclature protects patients and builds public trust.
No medicine works in a bubble. Roflumilast brings its share of risks, so regulators have carved out strict handling and prescription standards. Occupational exposure is kept low through well-ventilated spaces, gloves, and closed systems during manufacturing. For patients, Roflumilast comes boxed with clear warnings about monitoring for mood shifts or unwanted weight loss, both flagged during early trials. Health workers have been trained to spot symptoms that might need an immediate switch to another medication. Sticking to the safety playbook isn’t paperwork; it keeps patients on track and reassures families worried about side effects.
Ask any pulmonary specialist about tough cases and they’ll likely mention severe, chronic COPD that doesn’t settle down even with multiple inhalers. That’s where Roflumilast finds its home. By reducing exacerbations—the dangerous flare-ups that land patients in the hospital—it gives folks a real shot at breathing easier. Recent research has nudged Roflumilast toward dermatology. Cream formulations, now heading through late-stage trials, could help people with stubborn plaque psoriasis who can’t tolerate steroids or systemic immunosuppressants. The drug’s knack for putting the brakes on runaway cell signaling means scientists keep testing it in asthma, bronchiectasis, and even inflammatory bowel disease. The real trick is picking just the right group of patients, those who stand to benefit the most without crossing a line into unacceptable risk.
Roflumilast’s story doesn’t end with one green light from health regulators. Research teams keep picking away at the details—tinkering with dosing, looking at new delivery routes, or trying fixed-dose combinations to simplify pill routines. Drug resistance hasn’t emerged yet, but that’s a priority for long-term studies. Scientists are also mapping out the ripple effects of the drug’s action, checking if dialing back PDE4 might affect other organs over years of use. New data is coming out on gene variants that predict which patients respond best, opening the door to a day where doctors can tailor Roflumilast prescriptions to an individual’s DNA instead of casting a wide net.
No one likes to think about medicine doing harm, but it’s irresponsible not to look for it. In toxicology studies, Roflumilast showed a lower risk of broad immune suppression compared to steroids, but elevated doses raised the odds of gastrointestinal trouble and mood disruptions. Rat studies flagged some potential issues with fetal development, so doctors are especially cautious around women who could be pregnant. Long-term cancer risk, once a real worry in lab animals, hasn’t panned out in big human populations so far, but most experts say it pays to watch for subtle trends as the years go by. Keeping honest about these risks matters—trust between patients and medicine starts with full transparency.
Roflumilast entered the scene as a focused answer to an urgent need, but its journey looks nowhere near finished. The molecule’s flexibility gives scientists room to test it for new uses—sometimes as a pill, sometimes as a cream, or even as an inhalable formula. If genetic screening can home in on the best candidates for treatment, doctors could raise benefits while lowering unwanted effects. Cost is a hurdle, especially for uninsured patients or health systems under strain, but the growing market for generics should bring the price within reach for more people. Watching Roflumilast’s story unfold reminds us why drug development thrives on curiosity, dogged research, and a commitment to putting safe, effective options within reach for those who need them most.
Roflumilast is a prescription medicine that targets a specific issue in the body—chronic inflammation in the lungs. It’s mostly given to people living with chronic obstructive pulmonary disease (COPD), especially those dealing with flare-ups far too often. COPD drags people down with breathlessness, coughing, and an uncomfortable, daily grind that limits what used to be easy tasks like walking a few blocks or climbing stairs.
I’ve watched people close to me wrestle with the realities of COPD. Steroids and inhalers only go so far; nothing dulls the persistent irritation in the lungs quite like a medication that gets to the core of inflammation. Roflumilast steps in as a phosphodiesterase-4 inhibitor. That simply means it helps quiet down the inflammation that keeps setting off the coughing and tightening of airways. Fewer flare-ups mean a chance to stay out of the hospital, spend more time at home, and keep some quality of life intact.
A large study featured in The New England Journal of Medicine found that people on roflumilast had fewer worsening episodes of COPD compared to those taking a placebo. For individuals who face flare-ups several times a year, even a modest reduction can make daily life less daunting. The drug works by lowering certain chemicals in the lungs that drive swelling and mucus production. This approach does more than just mask symptoms—it strikes the problem at its root.
Any honest look at roflumilast also has to cover its side effects. Some people taking it report losing weight, stomach upset, trouble sleeping, or feeling low. Doctors make sure to ask about depression or thoughts of self-harm before starting someone on this medicine. The potential for improvement sometimes gets clouded by these effects, especially for folks with underlying mental health struggles or frail frames already threatened by weight loss.
Access poses another challenge. Roflumilast costs more than many older medicines, and not every insurance plan covers it easily. Some patients never even hear about it because of these financial hurdles. This creates a gap between advances in science and real-life impact, something I’ve seen frustrate families and doctors alike. Without fair access, innovation gets stuck in the pharmacy, and people keep suffering needlessly.
Improving the awareness and affordability of roflumilast can change outcomes for those with tough-to-treat lung problems. More training for healthcare workers on how and when to use it can lead to fewer missed opportunities. Patient support programs, along with advocacy for insurance reform, can help break down barriers. Better conversations between doctors and patients about risks and benefits open the door for informed choices. For those with COPD who feel like the options keep running out, even one new approach can mean hope for a steadier, easier breath.
Roflumilast shows up a lot in discussions about COPD management. For many people, breathing problems get in the way of daily life. Doctors often recommend roflumilast when standard inhalers or treatments don’t do enough. Instead of being a rescue medication, roflumilast steps in to help prevent future flare-ups. It’s a pill, not an inhaler, and comes with its own list of challenges.
Stomach issues usually lead the pack. Nausea and diarrhea pop up in many experiences shared online and in clinics. I’ve talked to a few folks who had to stop or switch treatments because stomach upset kept them away from daily routines. With roflumilast, these digestive problems land hard in the first few weeks. Some get used to it after a month, but not everyone has that luck.
Weight loss often surprises patients. For some, the pounds melt away without effort, but that’s not always a good thing. I met a retired truck driver at a support group who struggled to keep up his strength. The doctor pointed to roflumilast as the likely cause. Medical studies back this up: people lose two to three kilograms on average after three months on this drug. Losing weight might sound appealing, but unintentional drops can spell trouble for older adults or people who already deal with muscle loss.
Headaches and trouble sleeping come next. These issues don’t always force people to quit the medication, but they do impact the mood and energy levels. My neighbor tried roflumilast last fall and remembers dragging through the days, wondering if his tiredness came from oxygen drops or poor sleep. A change in prescription helped, but it’s obvious these side effects shape real-world experience.
Depression and anxiety don’t show up in every case, but the FDA does warn about these risks. For anyone with a history of mental health struggles, caution makes sense. Over several months, I’ve seen patient stories on forums describing a dip in motivation or energy after starting the medication. Rather than brushing it off, bringing up mental changes at routine appointments makes a difference. Healthcare teams pay attention to these patterns and can make adjustments if needed.
Doctors often suggest taking roflumilast with food for stomach issues. It doesn’t erase the side effect, but it can help dull the impact. For those who lose too much weight, adding high-calorie shakes or smaller, frequent meals sometimes helps rebuild lost pounds. Anyone with existing mental health challenges should chat with their provider upfront—open communication goes a long way.
Regular check-ins matter. I met a pulmonologist who tracks new prescriptions with short follow-ups, just to catch problems before they get too heavy. This approach caught one man’s weight loss before he had to stop his daily walks. Pharmacists and support groups provide more advice about managing less serious annoyances, like headache and sleep disruption.
Living with COPD feels tough enough even without adding side effects from medication. Roflumilast can deliver real relief from breathing issues and reduce flare-ups that send people to the hospital. The key is making sure that relief doesn’t come with bigger problems than it solves. Still, as someone who’s seen both the benefits and the struggles, I keep coming back to the same idea: honest conversations and a willingness to adjust therapy keep people safer and more comfortable at home.
Roflumilast treats chronic obstructive pulmonary disease (COPD), a condition that brings breathlessness and wheezing. Doctors once leaned on inhalers or steroids, but pills like Roflumilast give another option. My father struggled to manage his COPD and never liked the dizzy spells from inhalers. When his pulmonologist suggested Roflumilast, we paid close attention to the instructions. It’s not just another pill you swallow without a thought—correct dosing and timing go a long way in keeping symptoms from flaring up.
A lot of folks believe more medicine means faster results, but with Roflumilast, sticking to the prescribed dose helps you avoid side effects and gives your body a chance to adjust. Most doctors start with a 250 microgram tablet once daily for the first four weeks, then step up to the usual 500 microgram daily dose. This way, the tummy gets used to it. During my dad’s first month on Roflumilast, he took it with a glass of water around breakfast time. Our pharmacist stressed the importance of picking one time each day that works for you—and then not missing doses.
Roflumilast doesn’t play well with skipping or doubling up on doses. If someone forgets, it’s better to just take the next scheduled dose and not try to ‘catch up’. Skipping around with medicine times leads to more nausea or headache. The same goes for crushing or splitting tablets—leave those tablets as they are.
Some medicines lock horns with Roflumilast, especially strong inducers like rifampin or carbamazepine, which can make it less reliable. Alcohol won’t ramp up the effects directly, but it brings its own risk of liver stress. At home, we checked the medicine cabinet for old prescriptions and made a list for the pharmacist. That extra step dodged any possible clash.
Taking Roflumilast with food keeps the stomach calm, especially in the first few days. A little bread or oatmeal helped my dad sidestep the queasiness that sometimes crept in. Oddly enough, grapefruit doesn’t seem to mess with this pill, but it still pays to ask about dietary do’s and don’ts if you take other medicines.
COPD doesn’t care about convenience. Sticking with the medication, even when side effects show up, means fewer flare-ups and less time in the hospital. Evidence shows Roflumilast can reduce the number of bad attacks, so it’s worth the minor early tradeoff of stomach pain or weight loss. When my father felt discouraged, his doctor pointed to real numbers: fewer ambulance rides, fewer nights in the ER.
A pill organizer next to a toothbrush, a reminder on the phone, a simple check mark on the calendar—these made it easier for my dad to turn Roflumilast into part of his routine. The lung specialist asked us to check in at follow-up visits, not just for refills but to weigh in, review side effects, and see if anything about the lifestyle needed tweaking.
COPD steals energy, but taking Roflumilast the right way can help keep people living on their own terms. Medicines work best with attention and care, not luck. Patients and their families should feel comfortable asking for tips and troubleshooting with health providers—nobody needs to figure it all out solo.
Folks struggling with severe chronic obstructive pulmonary disease, or COPD, sometimes look to roflumilast for relief. Doctors prescribe it for people whose symptoms linger despite common inhalers. The medication aims to reduce flare-ups, but it’s not a one-size-fits-all pill. I’ve met patients who’ve seen their lives change with better breathing, but I’ve also witnessed stories where the side effects far outweighed the benefits. Understanding who just shouldn’t take roflumilast means looking past the glossy marketing and thinking about what really happens after that prescription hits the pharmacy.
Liver disease and roflumilast do not play nice together. The drug relies on a healthy liver for breakdown, so anything less can send levels through the roof. Studies show people with moderate or severe liver impairment see higher concentrations of the drug, which pushes up risks for dangerous side effects like nausea, weight loss, and even psychiatric problems. A doctor running standard bloodwork can spot trouble, but plenty of folks don’t realize something’s brewing with their liver until medication tips the balance. If the liver isn’t healthy, this drug invites more problems.
Roflumilast is notorious for causing weight loss. Most patients lose a few pounds, but for anyone already thin or battling other illnesses, losing more weight can be reckless. Malnutrition creeps up quietly and weakens resilience, especially in older adults. The clinical trials paint a worrying picture—a handful of people just kept losing weight and couldn’t regain it while on the drug. If you don’t have weight to spare, crossing roflumilast off the list makes sense. Doctors should look for other COPD therapies that don’t chip away at a patient’s body reserves.
Mental health and roflumilast aren’t always compatible. The FDA actually flagged new or worsening depression, trouble sleeping, mood swings, anxiety, and even suicidal thoughts as known risks. Listening to patients matters here. Someone with a long, tough history of depression, PTSD, or previous suicide attempts may experience setbacks if they start on this drug. Families need to talk about any mental health struggles before anyone tries roflumilast. Mental health side effects can take the wind out of physical gains that might come from easier breathing.
No one has proven that roflumilast is safe in pregnancy or breastfeeding. Animal studies show risks, but nobody can promise the same wouldn’t happen with a human fetus or infant. For pregnant women, doctors don’t want to gamble with an unborn child’s future. Families should ask about alternatives and focus on medicines with a safer background during pregnancy and breastfeeding.
Anyone who’s ever had an allergic reaction to roflumilast or its ingredients should steer clear. Allergic reactions can slam the body fast—think swelling, trouble breathing, or hives—so it’s simple: don’t risk it. Pharmacists and doctors can flag allergies, but patients must feel safe announcing all past reactions before picking up the prescription.
Personal health history shapes every prescription. Doctors need full honesty, and families need clear conversations about symptoms, mental wellness, weight, and possible pregnancy. Pharmacists can double-check records for liver troubles or allergies, but patients must speak up. The real safety net is thoughtful communication, not a generic one-line warning on the box. For some, roflumilast brings relief; for others, it upends more than breathing. The best care matches the medicine to the human, never just the diagnosis.
Roflumilast helps people breathe easier when living with chronic obstructive pulmonary disease (COPD). It works by stopping inflammation in the airways. My neighbor, who has lived with COPD for years, started taking roflumilast after many rounds of inhalers and steroids. On the positive side, his coughing and flare-ups dropped noticeably. Stories like his echo in many pulmonary clinics across the country, but concerns about mixing roflumilast with other pills often crop up in every appointment.
Most folks with COPD are already on a handful of prescriptions. Heart problems, high blood pressure, and depression often creep up alongside breathing troubles. Roflumilast doesn’t do anything for those conditions, but it shares space with the drugs that do.
Trouble starts when the body plays referee. Roflumilast gets broken down by liver enzymes, especially CYP3A4 and CYP1A2. Some popular medicines interfere with these same enzymes. Take rifampicin for example—a standard tuberculosis drug—it speeds up enzyme action, breaking down roflumilast faster and making it less effective. Certain anti-seizure medications and St. John’s Wort do much of the same. On the flip side, some treatments slow liver enzymes—think ketoconazole for fungal infections or erythromycin for bacterial ones—leading to higher roflumilast levels in the blood and raising the risk of nausea, weight loss, or diarrhea.
It isn’t rare to see patients come in after starting a new prescription only to report feeling lousy. One patient in a busy hospital setting developed severe stomach upset right after beginning a new antidepressant with roflumilast. Her physician, knowing the possible interaction, checked dosing schedules and switched out her medication. She got back to her old self and improved her breathing too.
Blood thinners, some HIV medicines, and even common antibiotics can all pose issues. Each person’s liver works at its own speed; genetic quirks and age throw in plenty of extra variables. In a 2023 review published by the European Respiratory Journal, doctors noted the importance of double-checking every medicine for possible collision before giving the green light on roflumilast. The FDA’s medication guide repeats this advice, and pharmacists know to scan every list for possible “red flags.”
Relying on a single doctor’s memory or a crowded clinic’s workflow doesn’t cut it. Electronic medical records and drug interaction checkers catch most obvious risks, but patients do themselves no favors by skipping over-the-counter pills or herbal supplements in their medication list. I’ve lost count of how many times a person thought “natural” products couldn’t possibly matter, only for an unexpected side effect to show up later.
Open conversations make the biggest difference. Pharmacists can walk folks through the risks, and regular follow-ups help catch side effects early. We all hear stories of pills piled high on a bedside table, but matching up medications with expert review keeps things safer. Many pulmonologists also encourage carrying a current medication list to every appointment, allowing for quick checks and easy communication.
Roflumilast can help the right patients breathe easier, but mixing it with other prescriptions isn’t something to take lightly. Trusted sources—like the FDA, Mayo Clinic, or a pharmacist you know—offer solid advice backed by science. If you, your family member, or your patient draws roflumilast from the pharmacy, check every other bottle in the medicine cabinet. Peace of mind is easier to breathe in than any prescription.
| Names | |
| Preferred IUPAC name | 3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide |
| Other names |
Daxas Daliresp Libertek Zoryve |
| Pronunciation | /roʊˈfluːmɪlæst/ |
| Identifiers | |
| CAS Number | 162401-32-3 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Roflumilast**: ``` CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(=O)OC3=CC=CC(F)=C3Cl ``` |
| Beilstein Reference | 3586702 |
| ChEBI | CHEBI:75558 |
| ChEMBL | CHEMBL1214125 |
| ChemSpider | 24088810 |
| DrugBank | DB01656 |
| ECHA InfoCard | 03b4c2bc-5e14-444f-960d-f6990cd19f87 |
| EC Number | EC 4.6.1.2 |
| Gmelin Reference | 104357 |
| KEGG | D09650 |
| MeSH | D000068878 |
| PubChem CID | 10188973 |
| RTECS number | TC0G28925V |
| UNII | 6Z1XM64859 |
| UN number | UN number not assigned |
| Properties | |
| Chemical formula | C17H14Cl2N2O3 |
| Molar mass | 403.21 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.245 g/cm3 |
| Solubility in water | Slightly soluble |
| log P | 2.9 |
| Vapor pressure | 7.29E-16 mmHg at 25°C |
| Acidity (pKa) | 8.6 |
| Basicity (pKb) | 8.86 |
| Magnetic susceptibility (χ) | -62.3·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.613 |
| Dipole moment | 4.05 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 388.9 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1034.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5755 kJ/mol |
| Pharmacology | |
| ATC code | R03DX07 |
| Hazards | |
| Main hazards | May cause liver dysfunction, weight loss, psychiatric effects (depression, anxiety, suicidal thoughts), and gastrointestinal disturbances. |
| GHS labelling | GHS labelling of Roflumilast: `"Warning; H315, H319, H335"` |
| Pictograms | Take with or without food; Swallow whole, do not crush or chew; Keep out of reach of children |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | 1-1-0-HEALTH |
| Flash point | > Flash Point: 266.7 °C |
| Lethal dose or concentration | LD₅₀ (oral, rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Roflumilast: "132 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.5 mg once daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Claprophylline Cilomilast Trequinsin Apremilast |
